UniProt O60885
Bromodomain-containing protein 4 (O60885)
Bromodomain-containing protein 4 (UniProt O60885): 758 experimental structures and 1 predicted model on GenesisL1, 328 ligands bound, 155 pockets. Binding sites, druggability and experiment against prediction (TM-score) in GL1X.
- UniProt
- O60885
- Protein
- Bromodomain-containing protein 4
- Experimental structures
- 758
- Predicted models
- 1
- Ligands
- 328
- Pockets
- 155 · 70 records with a druggable one
Structures
759 records of O60885 in the MolNFT archive: 758 experimental, 1 predicted.
| Entry | Title | Method | Chains | Ligands | Pockets |
|---|---|---|---|---|---|
| 2I8N | Solution structure of the second bromodomain of Brd4 | solution nmr | A | — | — |
| 2I8N | Solution structure of the second bromodomain of BRD4 | solution nmr | A | — | — |
| 2LSP | solution structures of BRD4 second bromodomain with NF-kB-K310ac peptide | solution nmr | B | — | — |
| 2LSP | Solution structures of BRD4 second bromodomain with nf-kb-K310AC peptide | solution nmr | B | — | — |
| 2MJV | Solution structures of second bromodomain of Brd4 with di-acetylated Twist peptide | solution nmr | B | — | — |
| 2MJV | Solution structures of second bromodomain of BRD4 with di-acetylated twist peptide | solution nmr | B | — | — |
| 2N3K | Human Brd4 ET domain in complex with MLV Integrase C-term | solution nmr | A | — | — |
| 2N3K | Human BRD4 et domain in complex with mlv integrase C-term | solution nmr | A | — | — |
| 2NCZ | Solution NMR structures of BRD4 ET domain in complex with NSD3_1 peptide | solution nmr | A | — | — |
| 2NCZ | Solution NMR structures of BRD4 et domain in complex with NSD3_1 peptide | solution nmr | A | — | — |
| 2ND0 | Solution NMR structures of BRD4 ET domain with LANA peptide | solution nmr | A | — | — |
| 2ND0 | Solution NMR structures of BRD4 et domain with lana peptide | solution nmr | A | — | — |
| 2ND1 | Solution NMR structures of BRD4 ET domain in complex with NSD3_3 peptide | solution nmr | A | — | — |
| 2ND1 | Solution NMR structures of BRD4 et domain in complex with NSD3_3 peptide | solution nmr | A | — | — |
| 2NNU | Crystal Structure of the Papillomavirus DNA Tethering Complex E2:Brd4 | x-ray diffraction | B | — | — |
| 2NNU | Crystal structure of the papillomavirus DNA tethering complex E2:BRD4 | x-ray diffraction | B | — | — |
| 2OSS | Crystal structure of the Bromo domain 1 in human Bromodomain Containing Protein 4 (BRD4) | x-ray diffraction | A | — | — |
| 2OSS | Crystal structure of the bromo domain 1 in human bromodomain containing protein 4 (BRD4) | x-ray diffraction | A | — | — |
| 2OUO | Crystal Structure of the Bromo domain 2 in human Bromodomain Containing Protein 4 (BRD4) | x-ray diffraction | A | — | — |
| 2OUO | Crystal structure of the bromo domain 2 in human bromodomain containing protein 4 (BRD4) | x-ray diffraction | A | — | — |
| 2YEL | Crystal Structure of the First Bromodomain of Human Brd4 with the inhibitor GW841819X | x-ray diffraction | A | — | — |
| 2YEL | Crystal structure of the first bromodomain of human BRD4 with the inhibitor GW841819X | x-ray diffraction | A | — | — |
| 2YEM | Crystal Structure of the Second Bromodomain of Human Brd4 with the inhibitor GW841819X | x-ray diffraction | A, B | — | — |
| 2YEM | Crystal structure of the second bromodomain of human BRD4 with the inhibitor GW841819X | x-ray diffraction | A, B | — | — |
| 3MXF | Crystal Structure of the first bromodomain of human BRD4 in complex with the inhibitor JQ1 | x-ray diffraction | A | — | — |
| 3MXF | Crystal structure of the first bromodomain of human BRD4 in complex with the inhibitor JQ1 | x-ray diffraction | A | — | — |
| 3P5O | Crystal Structure of the First Bromodomain of Human Brd4 in complex with IBET inhibitor | x-ray diffraction | A | — | — |
| 3P5O | Crystal structure of the first bromodomain of human BRD4 in complex with ibet inhibitor | x-ray diffraction | A | — | — |
| 3SVF | Crystal Structure of the first bromodomain of human BRD4 in complex with a dihydro-quinazolin ligand | x-ray diffraction | A | — | — |
| 3SVF | Crystal structure of the first bromodomain of human BRD4 in complex with a dihydro-quinazolin ligand | x-ray diffraction | A | — | — |
| 3SVG | Crystal Structure of the first bromodomain of human BRD4 in complex with a 3,5-dimethylisoxazol… | x-ray diffraction | A | — | — |
| 3SVG | Crystal structure of the first bromodomain of human BRD4 in complex with a 3,5-dimethylisoxazol… | x-ray diffraction | A | — | — |
| 3U5J | Crystal Structure of the first bromodomain of human BRD4 in complex with Alprazolam | x-ray diffraction | A | — | — |
| 3U5J | Crystal structure of the first bromodomain of human BRD4 in complex with alprazolam | x-ray diffraction | A | — | — |
| 3U5K | Crystal Structure of the first bromodomain of human BRD4 in complex with Midazolam | x-ray diffraction | A, B, C, D | — | — |
| 3U5K | Crystal structure of the first bromodomain of human BRD4 in complex with midazolam | x-ray diffraction | A, B, C, D | — | — |
| 3U5L | Crystal Structure of the first bromodomain of human BRD4 in complex with a benzo-triazepine ligand… | x-ray diffraction | A | — | — |
| 3U5L | Crystal structure of the first bromodomain of human BRD4 in complex with a benzo-triazepine ligand… | x-ray diffraction | A | — | — |
| 3UVW | Crystal Structure of the first bromodomain of human BRD4 in complex with a diacetylated histone 4… | x-ray diffraction | A | — | — |
| 3UVW | Crystal structure of the first bromodomain of human BRD4 in complex with a diacetylated histone 4… | x-ray diffraction | A | — | — |
| 3UVX | Crystal Structure of the first bromodomain of human BRD4 in complex with a diacetylated histone 4… | x-ray diffraction | A | — | — |
| 3UVX | Crystal structure of the first bromodomain of human BRD4 in complex with a diacetylated histone 4… | x-ray diffraction | A | — | — |
| 3UVY | Crystal Structure of the first bromodomain of human BRD4 in complex with a diacetylated histone 4… | x-ray diffraction | A | — | — |
| 3UVY | Crystal structure of the first bromodomain of human BRD4 in complex with a diacetylated histone 4… | x-ray diffraction | A | — | — |
| 3UW9 | Crystal Structure of the first bromodomain of human BRD4 in complex with a diacetylated histone 4… | x-ray diffraction | A, B, C, D | — | — |
| 3UW9 | Crystal structure of the first bromodomain of human BRD4 in complex with a diacetylated histone 4… | x-ray diffraction | A, B, C, D | — | — |
| 3ZYU | Crystal Structure of the first bromodomain of human BRD4 in complex with I-BET151(GSK1210151A) | x-ray diffraction | A, B | — | — |
| 3ZYU | Crystal structure of the first bromodomain of human BRD4 in complex with I-BET151(GSK1210151A) | x-ray diffraction | A, B | — | — |
| 4A9L | N-terminal bromodomain of human BRD4 with 1,3-dimethyl-6-(morpholine… | x-ray diffraction | A | — | — |
| 4A9L | N-terminal bromodomain of human BRD4 with 1,3-dimethyl-6-(… | x-ray diffraction | A | — | — |
| 4BJX | N-terminal bromodomain of human BRD4 with GSK1324726A (I-BET726) | x-ray diffraction | A | — | — |
| 4BJX | N-terminal bromodomain of human BRD4 with GSK1324726A (I-BET726) | x-ray diffraction | A | — | — |
| 4BW1 | The first bromodomain of human BRD4 in complex with 3,5 dimethylisoxaxole ligand | x-ray diffraction | A | — | — |
| 4BW1 | The first bromodomain of human BRD4 in complex with 3,5 dimethylisoxaxole ligand | x-ray diffraction | A | — | — |
| 4BW2 | The first bromodomain of human BRD4 in complex with 3,5 dimethylisoxaxole ligand | x-ray diffraction | A | — | — |
| 4BW2 | The first bromodomain of human BRD4 in complex with 3,5 dimethylisoxaxole ligand | x-ray diffraction | A | — | — |
| 4BW3 | The first bromodomain of human BRD4 in complex with 3,5 dimethylisoxaxole ligand | x-ray diffraction | A | — | — |
| 4BW3 | The first bromodomain of human BRD4 in complex with 3,5 dimethylisoxaxole ligand | x-ray diffraction | A | — | — |
| 4BW4 | The first bromodomain of human BRD4 in complex with 3,5 dimethylisoxaxole ligand | x-ray diffraction | A | — | — |
| 4BW4 | The first bromodomain of human BRD4 in complex with 3,5 dimethylisoxaxole ligand | x-ray diffraction | A | — | — |
699 records more on the page itself.
Ligands
- NA · Sodium ion · in 32 records
- NO3 · Nitrate ion · in 26 records
- CL · Chloride ion · in 12 records
- 0S6 · methyl [(6S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl]acetate · in 4 records
- 82Y · N-hydroxy-4-[5-(morpholin-4-yl)-7-oxo-7H-thieno[3,2-b]pyran-3-yl]benzamide · in 4 records
- HCC · 2',4,4'-trihydroxychalcone · in 4 records
- LOC · N-[(7S)-1,2,3,10-tetramethoxy-9-oxo-6,7-dihydro-5H-benzo[d]heptalen-7-yl]ethanamide · in 4 records
- 4K4 · 2-[(2-methoxy-4-{[4-(4-methylpiperazin-1-yl)piperidin-1-yl]carbonyl}phenyl)amino]-5,11-dimethyl-5,11-dihydro-6H-pyrimido[4,5-b][1,4]benzodiazepin-6-one · in 3 records
- 5W2 · 4-[[4-[[3-(~{tert}-butylsulfonylamino)-4-chloranyl-phenyl]amino]-5-methyl-pyrimidin-2-yl]amino]-2-fluoranyl-~{N}-(1-methylpiperidin-4-yl)benzamide · in 3 records
- ACE · Acetyl group · in 3 records
- IOD · Iodide ion · in 3 records
- QYV · 4-[2-(2,4-difluorophenoxy)-5-(methylsulfonyl)phenyl]-N-ethyl-6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-2-carboxamide · in 3 records
- SQH · 2-[3,4-bis(oxidanyl)phenyl]-7,8-bis(oxidanyl)chromen-4-one · in 3 records
- YF6 · N-(1-[1,1-di(pyridin-2-yl)ethyl]-6-{1-methyl-6-oxo-5-[(piperidin-4-yl)amino]-1,6-dihydropyridin-3-yl}-1H-indol-4-yl)ethanesulfonamide · in 3 records
- 2IR · N,N-dimethyl-2-[(3R)-3-(5-{2-[2-methyl-5-(propan-2-yl) phenoxy]pyrimidin-4-yl}-4-[4-(trifluoromethyl)phenyl]-1H-imidazol-1-yl)pyrrolidin-1-yl]ethan-1-amine · in 2 records
- 4OW · N-[2-chloro-5-({2-[3-fluoro-4-(1-methylpiperidin-4-yl) anilino]-5-methylpyrimidin-4-yl}amino)phenyl]-2-methylpropane-2-sulfonamide · in 2 records
- 4WG · 2-{[2-ethoxy-4-(4-hydroxypiperidin-1-yl)phenyl]amino}-5,11-dimethyl-5,11-dihydro-6H-pyrimido[4,5-B][1, 4]benzodiazepin-6-one · in 2 records
- 53W · 5-(3,5-dimethyl-1,2-oxazol-4-yl)-2-[2-(4-methoxyphenyl)ethyl]-1-[2-(morpholin-4-yl)ethyl]-1H-benzimidazole · in 2 records
- 5E3 · ~{N}-(3-ethyl-6-methoxy-1,2-benzoxazol-5-yl)-2-methoxy-benzenesulfonamide · in 2 records
- 5MJ · 3-chloranyl-~{N}-(4-methoxyphenyl)-4-[(2-methyl-3-oxidanylidene-cyclopenten-1-yl)amino]benzamide · in 2 records
- 6JF · 4-{6-(3,5-dimethyl-1,2-oxazol-4-yl)-1-[(1S)-1-(pyridin-2-yl)ethyl]-1H-pyrrolo[3,2-b]pyridin-3-yl}benzoic acid · in 2 records
- 6TB · 4-[[(7~{R})-8-cyclopentyl-7-ethyl-5-methyl-6-oxidanylidene-7~{H}-pteridin-2-yl]-methyl-amino]-3-methoxy-~{N}-(1-methylpiperidin-4-yl)benzamide · in 2 records
- 6XH · 1-[3-[[2-fluoranyl-4-(1-methylpyrazol-4-yl) phenyl]amino]-1-[(3~{S})-oxolan-3-yl]-6,7-dihydro-4~{H}-pyrazolo[4,3-c]pyridin-5-yl]ethanone · in 2 records
- 6XW · 5-(5-aminopyridin-3-yl)-8-(((3R,4R)-3-((1,1-dioxidotetrahydro-2H-thiopyran-4-yl)methoxy)piperidin-4-yl)amino)-3-methyl-1,7-naphthyridin-2(1H)-one · in 2 records
- 6XX · 8-(((3R,4R,5S)-3-((4,4-difluorocyclohexyl)methoxy)-5-methoxypiperidin-4-yl)amino)-3-methyl-5-(5-methylpyridin-3-yl)-1,7-naphthyridin-2(1H)-one · in 2 records
- 759 · (2~{S},4~{R})-1-[(2~{S})-2-[2-[2-[2-[2-[2-[(9~{S})-7-(4-chlorophenyl)-4,5,13-trimethyl-3-thia-1,8,11,12-tetrazatricyclo[8.3.0.0^{2,6}]trideca-2(6),4,7,10,12-pentaen-9-yl]ethanoylamino]ethoxy]ethoxy]ethoxy]ethanoylamino]-3,3-dimethyl-butanoyl]-~{N}-[[4-(4-methyl-2,3-dihydro-1,3-thiazol-5-yl)phenyl]methyl]-4-oxidanyl-pyrrolidine-2-carboxamide · in 2 records
- 7CJ · 3-fluoro-N-[3-(2-oxopyrrolidin-1-yl)phenyl]benzene-1-sulfonamide · in 2 records
- 7EA · 6-(3,4-dimethoxyphenyl)-3-methyl-[1,2,4]triazolo[4,3-b]pyridazine · in 2 records
- 7OW · 1,3-dimethyl-5-[2-(oxan-4-yl)-3-[2-(trifluoromethyloxy)ethyl]benzimidazol-5-yl]pyridin-2-one · in 2 records
- 7QZ · N-{1-[1,1-di(pyridin-2-yl)ethyl]-6-(5-{[(2-fluorophenyl)carbamoyl]amino}-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-1H-indol-4-yl}-2,2,2-trifluoroethane-1-sulfonamide · in 2 records
Experiment against prediction
- 6VIZ chain B against the predicted model O60885: TM-score 0.99, RMSD 0.30 Å
- 6VIW chain C against the predicted model O60885: TM-score 0.99, RMSD 0.32 Å
- 5JWM chain A against the predicted model O60885: TM-score 0.99, RMSD 0.34 Å
- 5JWM chain B against the predicted model O60885: TM-score 0.99, RMSD 0.34 Å
- 6VIZ chain C against the predicted model O60885: TM-score 0.99, RMSD 0.35 Å
- 5UEQ chain A against the predicted model O60885: TM-score 0.99, RMSD 0.36 Å
- 5UVU chain A against the predicted model O60885: TM-score 0.99, RMSD 0.37 Å
- 5UVU chain A against the predicted model O60885: TM-score 0.99, RMSD 0.37 Å
- 7C6P chain A against the predicted model O60885: TM-score 0.99, RMSD 0.37 Å
- 5UVX chain B against the predicted model O60885: TM-score 0.99, RMSD 0.37 Å
Elsewhere
GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.